Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims

1. (Currently amended) A pharmaceutical composition for once daily administration comprising:

i) a controlled release formulation of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof; and

ii) an immediate release formulation of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable ~~derivative~~ salt thereof and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof;

said composition providing for the release of zidovudine within 3 - 6 hours.

2. (Currently amended) A pharmaceutical composition for once daily administration comprising:

i) one layer containing a controlled release formulation of 3'-azido-3'-deoxythymidine ~~or a pharmaceutically acceptable salt thereof~~; and

ii) a second layer containing an immediate release formulation of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one ~~or a pharmaceutically acceptable derivative thereof~~ and 3'-azido-3'-deoxythymidine ~~or a pharmaceutically acceptable salt thereof~~.

3. cancelled

4. (Previously presented) A pharmaceutical composition according to claim 1 wherein the controlled release formulation comprises a mixture of polymers.

5. (Previously presented) A pharmaceutical composition according to claim 4 wherein the polymers are hydroxypropylmethylcellulose of different viscosities.

6. (Previously presented) A pharmaceutical composition according to claim 1 wherein the amount of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one is from about 150 to about 450 mg per unit dosage form.

7. (Previously presented) A pharmaceutical composition according to claim 1 wherein the amount of 3'-azido-3'-deoxythymidine is from about 100 to about 750 mg per unit dosage form.

8. (Previously presented) The pharmaceutical composition according claim 1 wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one is provided substantially free of the corresponding (+)-enantiomer.

9. (Previously presented) The pharmaceutical composition according to claim 1 wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one is provided such that the corresponding (+)-enantiomer is present in an amount of not more than about 5% w/w of the amount of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

10. cancelled.

11. (Previously presented) A pharmaceutical composition according to claim 1 in the form of a bilayer tablet or multilayer tablet.

12. (Previously presented) A pharmaceutical composition according to claim 1 in the form of a bilayer tablet.

13. (Previously presented) A pharmaceutical composition according to claim 1 in the form of a tablet within a tablet.

14. (Previously presented) A method for the treatment of an HIV infection in a human comprising administering a pharmaceutical composition according to claim 1.

15. (Previously presented) A pharmaceutical composition for once daily administration comprising:

i) a controlled release formulation of 3'-azido-3'-deoxythymidine; and

ii) an immediate release formulation of 3'-azido-3'-deoxythymidine and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

16. cancelled

17. (Previously presented) A pharmaceutical composition according to claim 1 wherein the salt of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one is a mesylate salt.